The GMRF Clinical Trials Unit is currently recruiting for the following clinical trials in genitourinary cancer:

PROTOCOL: (MK3475-B96) (PI: DR Jeff GoH)
SHORT TITLE: KEYNOTE B96

Protocol Title: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Lay Title: Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

Click here for more information

PROTOCOL: C3441052 (TALAPRO-3) (PI: DR JEFF GOH)

Protocol Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Lay Title: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Click here for more information

RETURN TO CLINICAL TRIALS PAGE